Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus ZOLEDRONIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus ZOLEDRONIC ACID.
ACTONEL vs ZOLEDRONIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
5 mg intravenously over at least 15 minutes once yearly for Paget disease or osteoporosis; 4 mg intravenously over at least 15 minutes every 3-4 weeks for hypercalcemia of malignancy or multiple myeloma/bone metastases.
None Documented
None Documented
Clinical Note
moderateZoledronic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Zoledronic acid
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zoledronic acid."
Clinical Note
moderateCarprofen + Zoledronic acid
"The risk or severity of adverse effects can be increased when Carprofen is combined with Zoledronic acid."
Clinical Note
moderateTerminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal half-life is approximately 146 hours (6 days), reflecting slow release from bone; clinical effect persists beyond this due to prolonged binding to hydroxyapatite.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Primarily renal (30-40% unchanged in urine over 24h, accounting for ~50% of total clearance); negligible biliary or fecal elimination (<1%).
Category C
Category D/X
Bisphosphonate
Bisphosphonate
Thalidomide + Zoledronic acid
"The risk or severity of adverse effects can be increased when Thalidomide is combined with Zoledronic acid."